Search for a trial

A Phase 2a, Double-Blind, Randomized, Placebo-Controlled Study of Ravagalimab in Subjects with Moderately to Severely Active Primary Sjogren's Syndrome.

To evaluate the safety and efficacy of ravagalimab vs placebo for the treatment of primary Sjogren's syndrome (pSS) in subjects with moderately to severely active primary Sjogren's syndrome (pSS).

A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of
Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

The main objective of Study M15-722 is to characterize the efficacy, safety, and tolerability of ravagalimab (ABBV-323) as induction treatment in subjects with moderately to severely active UC.